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ABSTRACT
Background. Blood pressure (BP) control and reduction of
urinary protein excretion using agents that block the renin–
angiotensin aldosterone system are the mainstay of therapy for
chronic kidney disease (CKD). Research has conﬁrmed the ben-
eﬁts in mild CKD, but data on angiotensin-converting enzyme
inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in
advanced CKD are lacking. In the STOP-ACEi trial, we aim to
conﬁrm preliminary ﬁndings which suggest that withdrawal of
ACEi/ARB treatment can stabilize or even improve renal func-
tion in patients with advanced progressive CKD.
Methods. The STOP-ACEi trial (trial registration: current con-
trolled trials, ISRCTN62869767) is an investigator-led multi-
centre open-label, randomized controlled clinical trial of 410
participants with advanced (Stage 4 or 5) progressive CKD re-
ceiving ACEi, ARBs or both. Patients will be randomized in a
1:1 ratio to either discontinue ACEi, ARB or combination of
both (experimental arm) or continue ACEi, ARB or combin-
ation of both (control arm). Patients will be followed up at
3 monthly intervals for 3 years. The primary outcome measure
is eGFR at 3 years. Secondary outcome measures include the
number of renal events, participant quality of life and physical
functioning, hospitalization rates, BP and laboratory measures,
including serum cystatin-C. Safety will be assessed to ensure
that withdrawal of these treatments does not cause excess
harm or increase mortality or cardiovascular events such as
heart failure, myocardial infarction or stroke.
Results. The rationale and trial design are presented here. The
results of this trial will show whether discontinuation of ACEi/
ARBs can improve or stabilize renal function in patients with
advanced progressive CKD. It will show whether this simple
intervention can improve laboratory and clinical outcomes,
including progression to end-stage renal disease, without caus-
ing an increase in cardiovascular events.
Keywords: angiotensin-converting enzyme inhibitor (ACEi),
angiotensin II receptor blocker (ARB), chronic kidney disease,
eGFR, randomized controlled trial
INTRODUCTION
Chronic kidney disease (CKD), Stages 3–5, affects 1 in 10 adults
in the UK and reﬂects progressive scarring of the kidneys re-
gardless of the original disease and is associated with a high
prevalence of cardiovascular disease [1]. Advanced CKD (Stage
4 or 5) is associated with a signiﬁcantly increased risk of death
[hazard ratio (HR): 3.6; 95% conﬁdence interval (CI) 3.2–4.0]
[2] and a 50-fold increased requirement for dialysis, in com-
parison with age-matched individuals with presumed normal
kidney function [3–6]. Advanced CKD has a major negative
impact on a range of other clinical outcomes including quality
of life [7, 8] and carries a high economic burden either through
associated cardiovascular or metabolic bone disease or due to
the high cost of renal dialysis (∼£30 000/year).
Irrespective of the underlying cause of CKD, attention
has focused primarily on blood pressure (BP) control and
reduction of urinary protein excretion using agents that block
the renin–angiotensin aldosterone system and reduce intra-
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glomerular pressure over and above their effect on BP. Studies
by Lewis et al. [9, 10] and Brenner et al. [11] have shown that
angiotensin-converting enzyme inhibitor (ACEi) and angioten-
sin receptor blockers (ARBs) reduce the progression of renal
disease [12–16]. Data from the HOPE, LIFE and ALLHAT
studies have conﬁrmed the beneﬁt of ACEi use in mild CKD
[estimated glomerular ﬁltration rate (eGFR) >60 mL/min/
1.73m2 with proteinuria or structural defects] [17–20].
Few studies have included patients with advanced CKD at
baseline. Moreover, it is difﬁcult to dissociate the beneﬁcial effect
of ACEi from BP control. Indeed, in the HOPE sub-study using
24-h ambulatory BP in place of ofﬁce BP, there was a signiﬁcant
reduction in BP from baseline in patients assigned to ramipril,
which may have been an important mediator of beneﬁt [18].
Ruggenenti et al. in a post hoc analysis of 322 patients suggested
that therapy should be offered to all patients with CKD, even
those with a GFR between 10 and 30 mL/min/1.73 m2 [21]. In
this seminal study, there was no ‘nephroprotective’ effect when
baseline proteinuria was <1.5 g/24 h, suggesting that the beneﬁ-
cial effects of ACEi may be limited to those with ‘pure’ glomeru-
lar disease rather than those with low-level proteinuria who may
have ischaemicCKD.ACochrane review of 49 studies containing
12 067 diabetic patients at all stages of CKD found that ACEi and
ARBs improved hard end point [end-stage renal disease (ESRD)]
and other outcomes, and appeared to reduce mortality (relative
risk 0.78; 95% CI 0.61–0.98) [22]. The authors, however, cau-
tioned against the conclusion that ACEi prevents progression
of CKD, suggesting that any initial beneﬁt may be due to their
anti-proteinuric effects (probably reﬂecting better overall BP
control), that there was little robust evidence of beneﬁt in ad-
vanced CKD and that conclusions were based mainly on com-
posite end points [22].
The rigor of some of these studies, which failed to dissociate
renoprotective from antihypertensive effects of ACEi/ARBs
[18], is now being questioned. Renoprotection from ACEi/
ARBmay be lost in more advanced disease where signiﬁcant is-
chaemic nephropathy is present. This hypothesis is supported
by reports in diabetic and non-diabetic patients with CKD in-
dicating that ACEi/ARBs may accelerate renal progression, in
spite of a beneﬁcial anti-proteinuric effect [23–25]. Combined
ACEi/ARB treatment has been shown to worsen renal out-
comes in patients at high cardiovascular risk and increases
the risk of hyperkalaemia and acute kidney injury [26–28].
The Telmisartan Randomized Assessment Study in ACE in-
tolerant subjects with cardiovascular disease (TRANSCEND)
demonstrated both a greater decline in eGFR and greater inci-
dence of doubling of serum creatinine on Telmisartan (HR 1.59;
95% CI 1.04–2.41) [29].
In a recent observational study, withdrawal of ACEi/ARB
therapy in 52 older patients with advanced CKD led to a
mean increase in eGFR of 10 mL/min/1.73 m2 over 12 months
and an increase or stabilization in eGFR in all but four patients.
There was a small increase in BP but no change in risk of car-
diovascular events [30]. There was also an association between
the increase in BP levels upon discontinuation of ACEi/ARB
and improved renal function [31]. The close interaction of
the kidney and the heart is critical to survival, and the risk fac-
tors for poor cardiovascular outcomes in the general population
and in early CKD are associated with better outcomes in ad-
vanced CKD [32, 33]. There are no studies assessing the beneﬁts
of ACEi/ARB therapy in cardiovascular risk reduction in ad-
vanced non-dialysis CKD. Indeed, although lowering BP re-
duces cardiovascular events, evidence suggests that ACEi/
ARBs are not superior to other antihypertensives in this regard
[34, 35]. Several randomized controlled studies in dialysis
patients have shown increased cardiovascular events with the
use of ACEi [36–38]. Indeed, the rate of decline of renal func-
tion remains a strong predictor of mortality [39–41].
RESEARCH QUESTION
Does a strategy of discontinuing ACEi, ARBs or their combin-
ation in patients with advanced (Stage 4 or 5) progressive CKD
lead to stabilization or improvement in renal function over a
3-year follow-up period, provided that good BP control is main-
tained with other agents, compared with a strategy of continu-
ing ACEi and/or ARB?
MATERIALS AND METHODS
Study design
STOP-ACEi (trial registration: current controlled trials,
ISRCTN62869767) is an investigator-led, multicentre, open-
label, randomized controlled clinical trial of 410 participants
aged 18 years or over with advanced (Stage 4 or 5) progressive
CKD receiving ACEi, ARBs or both. Patients will be followed up
3 monthly for 3 years (Figure 1).
Recruitment
Participants will be recruited from at least 15 UK renal units.
Site staff will screen for potential eligible participants using the
inclusion/exclusion criteria. If the participant is interested in
taking part, the trial will be discussed with them in detail,
and they will have the opportunity to ask questions. Participant
eligibility will be conﬁrmed with regard to the inclusion and ex-
clusion criteria, and informed consent will be sought.
Inclusion and exclusion criteria
Inclusion criteria are as follows:
• Aged ≥18 years (male or female)
• CKD Stage 4 or 5 [eGFR <30 mL/min/1.73 m2 using the
modiﬁcation of diet in renal disease (MDRD) equation] and
must not have received a kidney transplant or be on dialysis
• Progressive deterioration in renal function (fall in an eGFR
of >2 mL/min/year over previous 24 months) as measured
by linear regression analysis based on a minimum of three
eGFRmeasurements, with at least one reading from the pre-
vious 3 months
• Treatment with either an ACEi or ARB or a combination of
both for >6 months with at least 25% of the maximum
recommended daily dose
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• Resting BP ≤160/90 mmHg when measured in accordance
with British Hypertension Society guidelines in clinic or re-
cent home BP reading within the previous month or a 24-h
ambulatory BP measurement within the last 3 months
• At least 3 months of specialist renal follow-up
• Written, signed informed consent to the trial
Exclusion criteria are as follows:
• Aged <18 years
• Uncontrolled hypertension (>160/90 mmHg) or require-
ment for ﬁve or more agents to control BP
• Undergoing dialysis therapy
• Previous kidney transplant
• Any condition that, in the opinion of the investigator,
makes the participant unsuitable for trial entry due to progno-
sis/terminal illness with a projected survival of <12 months
• History of myocardial infarction or stroke in preceding
3 months
• Participation in an interventional research study in preced-
ing 6 weeks
• Pregnancy conﬁrmed by positive pregnancy test or
breastfeeding
• Inability to provide informed consent (e.g. due to cognitive
impairment)
• Immune-mediated renal disease requiring disease-speciﬁc
treatment
• Known drug or alcohol abuse
• Inability to comply with the trial schedule and follow-up
Study enrolment and randomization
Following informed consent and completion of the baseline
assessments, participants will be randomized into the trial in a
1∶1 ratio to either continue with their ACEi and/or ARB treat-
ment (control arm) or to discontinue their ACEi and/or ARB
treatment (experimental arm). Randomization will be provided
by a computer-generated programme at the Clinical Trials Unit,
using a minimization algorithm to ensure balance between the
F IGURE 1 : Schema for STOP-ACEi trial. BCP, biochemical proﬁle (including urea and electrolytes and liver function tests); BMI, body mass
index; FBC, full blood count; QOL, quality of life.
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arms with regard to important clinical variables. Theminimiza-
tion variables will be diabetes (Type I diabetes, Type II diabetes
or non-diabetic), BP {mean arterial pressure [MAP] measured
as [(2 × diastolic) + systolic]/3; <100 or ≥100}, age (<65 or ≥ 65
years), proteinuria (protein:creatinine ratio (PCR) <100 or
≥100) and eGFR (<15 or ≥ 15 mL/min).
Study treatment
Active treatment (experimental). All ACEi and/or ARB
treatment will be discontinued. In order to compensate for the
loss of antihypertensive activity, additional antihypertensive
treatment will be commenced to keep BP within recommended
guidelines. Any antihypertensive agents used in routine clinical
practice are permitted to control BP throughout the trial, but
excluding ACEi or ARBs. The choice of antihypertensive will
depend on other treatment being taken by the participant and
will be at the discretion of the responsible clinician. Any antihy-
pertensive agent used in routine clinical practice is permitted, but
excluding ACEi and ARBs except as a last resort.
Control arm. Participants will continue on ‘standard’ care
and will continue with their ACEi and/or ARB treatment.
The choice and dose of ACEi and/or ARB will be at the discre-
tion of the responsible clinician.
Both treatment groups. In both groups, BP will be controlled
to the target pressure outlined in the National Institute for
Health and Care Excellence (NICE) Hypertension guideline
and NICE CKD guideline [42, 43] of ≤140/85 mmHg. The
monitoring of BP will be as per the NICE CKD guideline.
Blinding. Trial treatment will be open label, due to the prac-
tical difﬁculties and costs associated with using placebo in a trial
of drug withdrawal. However, the primary outcome measure is
an objective laboratory measure that reduces the need for blind-
ing. Additionally, investigators taking part in the trial will
remain blind to all trial outcome data for the duration of the
trial to minimize bias, with un-blinded data presented only to
the independent Data Monitoring and Ethical Committee
(DMEC).
Assessments
Patients will be assessed at 3 monthly intervals from baseline
to 3 years in the patient’s routine outpatient clinic visit as per
the trial schedule of assessments (Table 1) [42].
Demographic data (e.g. date of birth, gender, smoking sta-
tus, weight, height) and a detailed disease history (e.g. cardio-
vascular comorbidity, antihypertensive medications) will be
collected at baseline. BP will be recorded at each visit, and
changes to antihypertensive and other concomitant medica-
tions will be recorded. A 12-lead electrocardiogram (ECG),
quality of life (using KDQOL-SFTM v1.3) and physical func-
tion (using 6 min walk test) will be collected at baseline and
then annually.
For the purpose of the trial, urine and blood samples will be
taken at baseline and each 3 monthly assessment. These sam-
ples will be used for routine tests and additional tests as part
of the trial (Table 1).
Primary outcome measure
The primary outcome measure is difference in renal func-
tion measured using the MDRD four-variable eGFR at the
3 years of follow-up.
Table 1. Schedule of assessments
Trial visit number 1 Phone call 2 3 4 5 6 7 8 9 10 11 12 13
Month 0 3 6 9 12 15 18 21 24 27 30 33 36
Check eligibility against inclusion/exclusion criteria, informed consent,
randomization
✓
Demographic and lifestyle dataa ✓
Medical history including cardiovascular comorbidities and CKD
aetiology
✓
Height ✓
Weight and BMI ✓ ✓ ✓ ✓
BP ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
6 min walk test ✓ ✓ ✓ ✓
KDQoL-SF™ v1.3 questionnaire ✓ ✓ ✓ ✓
12-lead ECG ✓ ✓ ✓ ✓
Record data from existing cardiac echocardiograms ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Record medication changes including ESA dose ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Assess compliance with trial treatment allocation ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Adverse event documentation ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Lab assessments ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Routine tests (performed locally)b ✓ ✓ ✓ ✓
C-Reactive Protein (performed locally) ✓ ✓ ✓ ✓
Additional trial tests (analysed centrally)c ✓ ✓ ✓
Serum and urine samples taken for optional biomarker analysis
aTo include date of birth, gender, ethnicity, smoking status and alcohol intake.
bTo include creatinine, eGFR, haemoglobin, mean cell volume, mean corpuscular haemoglobin, platelets, sodium, potassium, bicarbonate, calcium, phosphate, alkaline phosphatase,
albumin, total protein, alanine transferase and urinary protein:creatinine or albumin:creatinine ratio.
cTo include cystatin-C, NT-proBNP and ACE/renin levels in a sample of participants.
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Secondary outcome measures
Renal events.
• The number of participants starting renal replacement ther-
apy or sustaining a >50% decline in eGFR
• Time taken to reach ESRD or need for renal replacement
therapy
Quality of life and physical function.
• Participant quality of life and well-being (KDQOL-SF™
v1.3 questionnaire)
• Participant physical function (6 min walk test)
Clinical events.
• Hospitalization rates from any cause
• BP
Laboratory measures.
• Serum cystatin-C
Safety.
• Safety of intervention related to potential harm (e.g. in-
creased cardiovascular events such as heart failure, myocar-
dial infarction, stroke or death, participant survival in each
group)
Mechanistic outcome measures
• Urine protein excretion
• Blood haemoglobin concentration
• Dose of erythropoietin stimulating agent (ESA) administered
Statistical considerations
Sample size. Anobservational study provided data on eGFR in
52 patients with advanced CKD in the 12 months prior to stop-
ping ACEi/ARB treatment, at the point of stopping ACEi/ARB
and 12 months after stopping (Table 2) [31]. These data form
the basis of the sample size calculation.
To err on the side of caution, the largest standard deviation was
used to estimate the variability in eGFR (i.e. SD of 16 mL/min/
1.73 m2) for the sample size calculation. To detect a minimum
relevant difference between groups of 5 mL/min/1.73 m2 (i.e.
effect size of 0.31) with 80% power and alpha = 0.05 (using a
two-sample t-test), a total of 410 participants (205 per group)
will need to be recruited (this includes allowance for
20% dropout). Data from Beddhu et al. who used propensity
scores in a multivariate model in Dialysis Morbidity
and Mortality Study Wave 2 patients showed that each
5-mL/min fall in MDRD GFR was associated with an
increased hazard of death in a multivariable Cox model
(HR 1.14; P = 0.002) [44].
Statistical analysis. The Statistical Analysis Plan will describe
the planned analyses for STOP-ACEi in full detail. A summary
of the main analyses are given here. All analysis will be based on
the intention to treat principle, and a P-value of <0.05 will be
considered statistically signiﬁcant. The primary outcome is
the continuous measure eGFR at 3 years. These data will be
summarized using means and standard deviations, with differ-
ences in means and 95% CIs reported. The two groups will be
compared at 3 years using both a two-sample t-test and ANCO-
VA to adjust for baseline values. Longitudinal plots of the data
over time will be constructed for visual presentation of the data.
As a secondary analysis, a repeatedmeasures analysis, including
a treatment by time cross-term, will be carried out on all data
across the 3 years of follow-up.
Continuous secondary outcomemeasures (e.g. BP, quality of
life) will be analysed in the same way as the primary outcome.
Categorical (dichotomous) outcomemeasures (e.g. hospitaliza-
tion rates) will compare the proportion of participants and
percentages using a χ2 test, with relative risks and 95% CIs re-
ported. Time-to-event outcomes (e.g. time to ESRD, mortality)
will be analysed using survival analysis and log-rank methods.
Kaplan–Meier survival curves will be constructed for visual
presentation of time-to-event comparisons. Treatment effects
will be expressed as HRs with 95% CIs.
Several a priori subgroup analyses with respect to the mini-
mization variables for both primary and secondary outcomes
will be performed. These analyses will be considered hypothesis
generating.
MONITORING
Safety reporting
It is expected that the risk of the trial intervention, withdrawal
of ACEi and/or ARB, will not be signiﬁcantly higher than that of
standard medical practice. The incidence of adverse events,
including cardiovascular events, will be closely monitored by
the trial oversight committees. All adverse events will be report-
able to the STOP-ACEi trial ofﬁce until each participant’s ﬁnal
assessment at 3 years.
Trial steering committee
An independent Trial Steering Committee will provide
oversight of the study. The independent members of this com-
mittee are Dr Richard Haynes (Consultant Nephrologist;
chair), Dr Nick Selby (Consultant Nephrologist) and Christo-
pher Allison (Patient Representative).
Table 2. Data that formed the basis of the sample size calculation
Time point relative to stopping
ACEi/ARB
eGFR (mL/min/1.73 m2),
mean ± SE (SD)
−12 months 22.9 ± 1.4 (10.1)
0 16.38 ± 1 (7.2)
+12 months 26.6 ± 2.2 (15.9)
eGFR in patients with CKD who underwent ACEi/ARB withdrawal in a previously
published study.
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Data monitoring committee
A DMEC will independently monitor the efﬁcacy and safety
analysis reports at least annually. The independent members of
this committee are Dr John Firth (Consultant Nephrologist;
chair), Dr Paul Kalra (Consultant Cardiologist) and Mrs Mer-
ryn Voysey (Statistician).
REGULATORY ASPECTS
The RCT will be conducted according to the standards of the
International Conference on Harmonisation-Good Clinical
Practice (GCP) and the Research Governance Framework for
Health and Social Care. Pharmaco-vigilance reporting will com-
ply with the Medicines for Human Use (Clinical Trials) Regula-
tions 2004 and Amended Regulations 2006. Written informed
consent will be provided by all patients prior to randomization
and any study-related procedures.
STOP-ACEi is sponsored by the Hull and East Yorkshire Hos-
pitals NHSTrust (R1578). TheMedicine andHealthcare Products
Regulatory Authority clinical trial authorization reference is
21411/0242/001-0001. The EudraCT number is 2013-003798-82.
ETHICAL COMMITTEE APPROVAL
Ethical approval for STOP-ACEi was granted by theNational Re-
search Ethics Service Committee Yorkshire and the Humber—
Leeds East (13/YH/0394) on 29 January 2014.
DISCUSSION
Studies on the effects of ACEi/ARB in advanced CKD are lack-
ing. In addition, published studies have failed to dissociate the
putative renoprotective effects that are speciﬁc for ACEi/ARBs
from their antihypertensive effect. Also, the beneﬁts of the as-
sociation between reducing protein excretion and the doubling
of serum creatinine have recently been challenged by clinical
trials such as ACCOMPLISH and ONTARGET, where a reduc-
tion in proteinuria/albuminuria was associated with accelerated
CKD decline. The results of STOP-ACEi will provide evidence
on whether discontinuation of ACEi/ARB is beneﬁcial to renal
function (improvement/stabilization) and improves other im-
portant parameters including laboratory (hyperkalaemia, an-
aemia) and clinical outcomes (hospitalization rates, physical
function and quality of life) without causing an increase in car-
diovascular events. It aims to clarify whether the beneﬁts of this
intervention outweigh the risks. It is, therefore, hoped that this
pivotal study can provide new ﬁndings to allow future consid-
eration of a large randomized controlled trial with mortality
outcomes in this important group of patients.
Trial status
STOP-ACEi opened to recruitment on 2 July 2014, and the
ﬁrst patient was recruited on 11 July 2014. As of 11 Sep 2015,
118 patients (29%) were recruited into the study.
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